Detail akcie Elicio Theraptcs Rg online

Business Summary: Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Angion Biomedica Corp revenues was not reported. Net loss decreased 16% to $31.9M. Lower net loss reflects Biopharmaceutical segment loss decrease of 8% to $28.9M. Basic Earnings per Share excluding Extraordinary Items increased from -$3.18 to -$2.13.